Abstract: Methods of using fibrillar proteins are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis.

Abstract: Methods of using fibrillar proteins are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis.

Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein.

Abstract: The present invention herein relates to a bioactive substance with mammalian B lymphocyte toxicity secreted by canine transmissible venereal tumor (CTVT) and its process. CTVT is the only mammalian tumor in nature that is transmitted through viable tumor cells. Transmission of CTVT between dogs is akin to an allograft. The isolation of bioactive substance secreted by CTVT includes the following steps: (1) store CTVT excised from canine skin in Hank's balanced salt solution (HBSS); (2) physically extract CTVT, tumor infiltrating lymphocytes and peripheral blood lymphocytes; (3) place CTVT in culture medium and physically obtain suspension fluid with B lymphocyte toxicity; (4) drive said suspension solution through protein filters with different pore sizes to obtain bioactive substance.